Dr. Todd Johnson, M.D. is the Chief Growth Officer at M2GEN, an oncology-focused health informatics solutions company with the mission to help patients get access to the best treatments by leveraging clinical and molecular data to accelerate the discovery, development, and delivery of tailored and more personalized therapies.
Dr. Todd Johnson is Chief Growth Officer for M2GEN. He previously served as Senior Advisor to Clayton, Dubilier & Rice in Healthcare/Real World Data, to which he brought a 20-year track record building and managing high-performing, innovative Life Sciences data and services businesses. His previous experiences include the founding and management of Optum’s Clinical Research Group, co-founding and serving as president and board member at CytoVas, a liquid biopsy company, Noble.MD, an innovative patient data platform sold to WellTrackOne, Abbott Labs/AbbVie’s pharmaceutical pipeline, and MDS / Celerion, a drug development business sold to Bain Capital. Early in his career, Dr. Johnson was a cancer biologist at the Dana-Farber Cancer Institute, and at the Peter Nowell lab at Penn. Dr. Johnson holds a Bachelor of Arts from Penn, an ABA from Oxford, an MD from the Perelman School of Medicine at the University of Pennsylvania, and an MBA from Wharton.